Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Somers

Thoracic Surgery (Cardiothoracic Vascular Surgery) Park Ridge, IL Medical Doctor

NPI 1376657643 CMS profile 289769

1875 W Dempster St Ste 520, Park Ridge, IL 60068

Open in the dashboard

General payments

$12,621

272 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Somers of Park Ridge, IL is reported in the CMS Open Payments database as having received $12,621 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,092 40
2024 General $2,690 57
2023 General $1,875 39
2022 General $1,739 38
2021 General $2,211 45
2020 General $483 14
2019 General $1,531 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Somers
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Jonathan Somers were reported at $2,092. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Jonathan Somers Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $1,531 $886 $178–$3,167 $163
2020 $483 $341 $108–$1,605 $114
2021 $2,211 $453 $125–$1,886 $132
2022 $1,739 $695 $180–$2,566 $149
2023 $1,875 $745 $205–$2,662 $160
2024 $2,690 $799 $214–$2,967 $164
2025 $2,092 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,700 37 payments
  2. Amgen Inc. $1,612 27 payments
  3. Abbott Laboratories $1,494 21 payments
  4. Novo Nordisk Inc $1,465 21 payments
  5. Medtronic, Inc. $1,060 16 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $1,055 19 payments
  7. Novartis Pharmaceuticals Corporation $868 31 payments
  8. Edwards Lifesciences Corporation $545 7 payments
  9. E.R. Squibb & Sons, L.L.C. $485 23 payments
  10. AstraZeneca Pharmaceuticals LP $470 25 payments
  11. Other $1,867 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,621 272 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,593 31 payments
  2. Repatha $1,469 25 payments
  3. Ozempic $763 10 payments
  4. JARDIANCE Diabetes $605 8 payments
  5. EPIC $595 7 payments
  6. LEQVIO $561 18 payments
  7. COREVALVE EVOLUT R $411 5 payments
  8. OPSUMIT $366 9 payments
  9. LINQ II $346 3 payments
  10. JARDIANCE Diabetes $324 10 payments
  11. Other $5,420 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$78,835

Medicare's payments for the services billed

Medicare patients

128

Average age 76

Services billed

175

42 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Heart failure 58%
Arthritis 47%
Chronic kidney disease 42%
Atrial fibrillation 41%
Diabetes 34%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $484
  • Lilly USA, LLC $10
$494 — —
Repatha
  • Amgen Inc. $319
$319 — —
OPSUMIT
  • Janssen Pharmaceuticals, Inc $131
  • Actelion Pharmaceuticals US, Inc. $71
$202 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $166
$166 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record